Power3 Medical Products, Inc. Chairs International Congress in China

Power3 Medical Products, Inc., a Leader in Neurodegenerative Disease and Cancer Diagnostic Biomarkers, Announces Its Chief Scientific Officer is Chair and Keynote Speaker at the BTI Life Sciences 2nd Annual Congress and Expo of Molecular Diagnostics in Beijing, China Power3 Medical Products, Inc. (OTCBB: PWRM), a leader in neurodegenerative disease and cancer biomarkers and diagnostic tests, announces further international recognition of validity as the company's President and CSO, Dr. Ira Goldknopf, will deliver an invited Keynote address and chair a session on "Biomarkers and Diagnostics in Personalized Medicine (Track 6- 4)," at the BIT Life Sciences 2nd International Congress and Expo of Molecular Diagnostics in Beijing, China, November 19-21, 2009. The Theme of the meeting is "New Leadership of Personalized Medicine." In his Keynote address, entitled "Principles of Omic Medicine Applied to Differential Diagnosis - Breast Cancer and Neurodegenerative Diseases," Dr. Goldknopf will discuss the "necessary fundamental principles" that BC-SeraPro?and NuroPro?exemplify which enable the company's biomarkers and tests to " more effectively address the unmet clinical needs that challenge us today." He will describe the company's unique position and ability to use biomarkers for testing in personalized medicine and the various facets that are required for discovery, validation and to commercialize a group of biomarkers. "For physicians to order a test for a patient, they first need to believe in it. That takes major international scientific acceptance and publication in peer-reviewed journals. This meeting is an excellent opportunity to showcase worldwide the strides we have made through refinements in our biomarkers and blood test for early stage detection of breast cancer (BC- SeraPro, GLOBE NEWSWIRE Aug. 20, 2009)," said Dr. Goldknopf. "Earlier presentations on Alzheimer's and Parkinson's disease biomarkers and tests were given at the annual meetings of the American Academy of Neurology in Seattle and the International Congress of Alzheimer's Disease in Vienna (NuroPro, World Stock Wire July 14, 2009). We recently published the Parkinson's disease biomarkers and test results in Biochemical and Biophysical Research Communications (Reuters Sept. 2, 2009), and more publications are in the works." "We are extremely proud and excited about the recognition of Dr. Goldknopf and Power3 by the opportunity to chair this session and present at this international meeting," said Ms. Helen Park, Power3;s CEO. "Dr. Goldknopf is the Keynote speaker and will feature new progress in clinical validation of the company's biomarkers and blood test for early stage diagnosis of breast cancer leading to commercialization." (Source: Business Wire)Air Jordan XI 11 Low